WebDec 4, 2024 · Dalbavancin, a semi-synthetic derivative of vancomycin, has lipophilic side chains which reduce the risk of cross-sensitivity to vancomycin. This case series … WebSep 15, 2007 · New treatment options for invasive MRSA infections include linezolid, daptomycin, tigecycline, and quinupristin/dalfopristin. Additionally, a number of new anti-MRSA compounds are in development, including novel glycopeptides (dalbavancin, telavancin, and oritavancin), ceftobiprole, and iclaprim.
Daptomycin - Infectious Diseases - Merck Manuals Professional Edition
Web• Alternatives for Vancomycin intolerance (not Corynebacterium and other skin flora Consider holding antibiotics until deep tissue cultures can be obtained in hemodynamically stable patients Preferred: Vancomycin* IV (see nomogram) vancomycin infusion reaction**) or allergy: Daptomycin* 6 mg/kg IV daily OR Linezolid 600 mg PO/IV q12h 6 … WebMar 7, 2024 · Daptomycin is a lipopeptide antimicrobial with activity against gram-positive organisms, including antimicrobial-resistant pathogens such as methicillin-resistant … greers mountain
Stevens-Johnson syndrome induced by the cross-reactivity …
WebTHE "BEST" ANTIBIOTIC SENSITIVITY CHART EVER (at least the best we could make) Created by James McCormack, BSc(Pharm), PharmD and Fawziah Lalji, BSc(Pharm), PharmD, FCSHP with assistance from Tim Lau Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC Gram Positive Cocci Anaerobes … WebCross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or ... (Table 1) and severity of reaction 2. Evaluate prior antibiotic tolerance history a. Review allergy documentation in EPIC to determine if previously tolerated beta-lactams are ... vancomycin, daptomycin, or linezolid) Clindamycin ... WebAug 1, 2024 · The rationale for use of DAP varied, with 41% receiving therapy secondary to an adverse event while on NAF or CFZ, 24% due to an additional need for vancomycin-resistant Enterococcus spp. coverage (all sites) or MRSA coverage (non-blood site), 21% with reported beta-lactam allergy, and 14% for other or unknown reasons. focal flow